Whitehawk insider receives 51,020-share stock grant
Whitehawk Therapeutics executive Bryan Ball reported a stock-based compensation grant on Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Whitehawk Therapeutics executive Bryan Ball reported a stock-based compensation grant on Common Stock. On May 14, 2026, he acquired 51,020 shares at an indicated value of $3.92 per share as a grant or award, rather than an open-market purchase. Following this award, his direct holdings in Whitehawk Therapeutics increased to 448,126 Common Stock shares, reflecting a routine compensation-related equity grant instead of a discretionary market trade.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 51,020 | $3.92 | $200K |
Key Figures
Key Terms
Form 4 regulatory
grant or award acquisition financial
non-derivative financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Bryan Ball report for Whitehawk Therapeutics (WHWK)?
At what price was Bryan Ball’s WHWK stock grant valued?
Was Bryan Ball’s WHWK Form 4 transaction a market buy or sell?
Does the Bryan Ball Form 4 for WHWK involve derivative securities or options?
AI-generated analysis. How Rhea-AI works. Not financial advice.